American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
- 1 September 2017
- journal article
- review article
- Published by Elsevier BV in Gastroenterology
- Vol. 153 (3), 835-857.e6
- https://doi.org/10.1053/j.gastro.2017.07.031
Abstract
No abstract availableKeywords
Funding Information
- National Library of Medicine training (T15LM011271)
- American College of Gastroenterology and Crohn’s and Colitis Foundation
- National Institutes of Health (5U01DK092239)
This publication has 83 references indexed in Scilit:
- Implementation of TPMT testingBritish Journal of Clinical Pharmacology, 2014
- Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2012
- Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's diseaseScandinavian Journal of Gastroenterology, 2010
- Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice PharmacologyGastroenterology Clinics of North America, 2010
- Timing of Myelosuppression During Thiopurine Therapy for Inflammatory Bowel Disease: Implications for Monitoring RecommendationsClinical Gastroenterology and Hepatology, 2009
- Adverse reactions to azathioprine cannot be predicted by thiopurine S‐methyltransferase genotype in Japanese patients with inflammatory bowel diseaseJournal of Gastroenterology and Hepatology, 2009
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986